# PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

> **NCT05928039** · PHASE4 · RECRUITING · sponsor: **University of Calgary** · enrollment: 297 (estimated)

## Conditions studied

- Crohn Disease

## Interventions

- **BIOLOGICAL:** TNFa Antagonist - Infliximab
- **BIOLOGICAL:** TNFa Antagonist - Adalimumab
- **BIOLOGICAL:** Anti-IL12/23 or anti-IL23 - Ustekinumab
- **BIOLOGICAL:** Anti-IL12/23 or anti-IL23 - Risankizumab
- **BIOLOGICAL:** Anti-integrin - Vedolizumab IV
- **BIOLOGICAL:** Anti-integrin - Vedolizumab IV and SC

## Key facts

- **NCT ID:** NCT05928039
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 297 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928039, "PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05928039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*